The field of oncology has witnessed a significant transformation with the advent of antibody-drug conjugates (ADCs), offering a promising avenue for treating various cancers, including breast cancer. This special issue of NPJ Breast delves into the innovations and hurdles surrounding ADCs in breast cancer therapy, shedding light on their mechanism of action, resistance mechanisms, clinical efficacy, biomarkers, and future prospects.
ADCs are tailored to enhance the targeted delivery of cytotoxic agents to cancer cells, showcasing superior efficacy compared to traditional chemotherapy. By merging the specificity of monoclonal antibodies with the potent cell-killing capabilities of chemotherapeutic drugs, ADCs not only target cancer cells directly but also bolster antitumor immune responses. Over the last decade, three ADCs have been developed and greenlit for breast cancer treatment, with others either awaiting approval or progressing through clinical trials.
This collection unites top-tier researchers and clinicians to explore pivotal themes, including understanding the mechanism of action of ADCs for efficient cancer cell eradication, evaluating the clinical efficacy through trial data to gauge response rates and patient survival enhancements, grappling with resistance mechanisms to ADCs, sequencing impacts, and devising strategies to surmount these challenges, showcasing novel ADC designs that capitalize on antibody engineering, linker technologies, and payload choices to amplify the therapeutic potential, and contemplating the future trajectory of ADCs in combinatorial therapies and personalized medicine within the breast cancer treatment landscape.
By furnishing a comprehensive perspective on the present state of ADC research and its implications for the future of breast cancer treatment, this collection aspires to pave the way for more effective and personalized therapeutic alternatives for breast cancer patients, thereby ushering in a new era in cancer care.
Key Takeaways:
– ADCs represent a promising frontier in breast cancer treatment, combining the precision of monoclonal antibodies with the cytotoxicity of chemotherapeutic agents.
– The collection underscores the critical role of ADCs in enhancing targeted cancer therapy, addressing challenges such as resistance mechanisms and the evolution of innovative ADC designs.
– Through a focus on the mechanism of action, clinical efficacy, and future directions of ADCs, the collection aims to shape the future landscape of breast cancer treatment towards more effective and personalized approaches.
Tags: monoclonal antibodies, antibody-drug conjugates
Read more on nature.com